Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Microbiota 7 - June 2019
  3. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 7 - June 2019
  3. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant
Gastroenterology

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant

Drug

Commented articles - Adult's section

By Pr. Harry Sokol
Gastroenterology and Nutrition Department, Saint-Antoine Hospital, Paris, France

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Faecal transplant preparation. A technician storing a prepared sample of human faecal matter in cold storage.

About this article

Author

Image_DT FMT H Sokol Prof Harry Sokol
Created 25 August 2021
Updated 19 August 2024

Commentary on the original publication by Taur et al. (Science Translational Medicine 2018)

Antibiotic treatment can deplete the commensal bacteria of a patient’s gut microbiota and, paradoxically, increase their risk of subsequent infections. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), antibiotic administration is essential for optimal clinical outcomes but significantly disrupts intestinal microbiota diversity, leading to loss of many beneficial microbes. Although gut microbiota diversity loss during allo-HSCT is associated with increased mortality, approaches to re-establish depleted commensal bacteria have yet to be developed. A randomized, controlled clinical trial has been initiated to compare autologous faecal microbiota transplantation (auto-FMT) versus no intervention; the intestinal microbiota profiles of 25 allo-HSCT patients (14 who received auto-FMT treatment and 11 control patients who did not) were analysed. Changes in gut microbiota diversity and composition revealed that the auto-FMT intervention boosted microbial diversity and re-established the intestinal microbiota composition that the patient had before antibiotic treatment and allo-HSCT. These results demonstrate the potential utility of faecal sample banking for auto-FMT for posttreatment remediation of a patient’s gut microbiota after microbiota-depleting antibiotic treatment during allo-HSCT.[1]

What do we know about this subject? 

Antibiotic treatment damages the intestinal microbiota and increases the risk of gastrointestinal infection. Although this effect has been recognized for more than 60 years, remediation of the antibiotic-depleted gut microbiota has yet to become standard clinical practice. In patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), antibiotics are routinely given to treat or reduce the risk of serious infection. Prospective studies of allo-HSCT patients demonstrated that the intestinal microbiota is markedly altered during treatment, with profound loss of obligate anaerobic bacteria including immunomodulatory species such as those belonging to the Clostridia class and Bacteroidetes phylum [2]. The clinical consequences of these alterations are also apparent in allo-HSCT: disruption of beneficial obligate anaerobes correlates with complications that include systemic infection with vancomycin-resistant Enterococcus (VRE), Clostridium difficile infection, and graft-versushost disease (GVHD).[2, 3] Overall, patients who lose gut microbiota diversity at the time of hematopoietic stem cell engraftment have higher rates of transplant-related death.[4]

What are the main insights from this study? 

Allo-HSCT patients remain immunocompromised for many months after engraftment, and although immunocompromised patients, including allo-HSCT recipients, have undergone heterologous FMT without side effects,[5] the authors reasoned that autologous FMT would be safer by minimizing the risk of exposure to potentially pathogenic microorganisms not previously encountered by the patient. The authors initiated a randomized, controlled clinical trial to determine the feasibility of auto-FMT for restoring the gut microbiota and for decreasing complications related to allo-HSCT. Here, they present an analysis of the gut microbiota compositional changes in 25 patients enrolled and randomized from whom faecal samples were longitudinally collected.

The authors first confirmed in their cohort of 753 patients (3,237 longitudinally collected faecal samples) that allo-HSCT and the different associated antibiotic treatments induced a marked decrease in gut microbiota diversity, reaching a nadir 5 days after allo-HSCT, which persisted for at least 6 weeks and which in most patients had not recovered at day 100 post-allo-HSCT.

Key points

  • The intestinal microbiota is markedly disrupted during allo-HSCT and this disruption can play a role in the associated complications.

  • Auto-FMT is a feasible and effective strategy for reconstitution of the microbiota after the disruption caused by allo-HSCT.

  • The consequences of microbiota reconstitution in terms of haematological outcomes remain to be evaluated.

Image

As part of the randomized study, faecal samples from patients collected before allo-HSCT were frozen at -80°C and stored. One to 5 weeks (mean, 13 days) after allo- HSCT, upon engraftment (defined by recovery of the neutrophil count to > 500/mm3), patients were re-evaluated and another faecal sample was taken. If there was a paucity of bacteria from the Bacteroidetes phylum, patients were randomized. The results of microbiota analyses from the first 25 evaluable patients (14 from the auto-FMT group and 11 from the control group) are presented. Auto-FMT was administered as a single retention enema after colonic preparation with polyethylene glycol, similar to the preparation for a colonoscopy. The authors show that auto-FMT not only restores the diversity of the intestinal microbiota but also its composition pre-allo-HSCT.

What are the consequences in practice?

microbiota and disruptions thereof play a role in the common infectious and non-infectious complications encountered during allo-HSCT. This first study shows that the collection and storage of a patient’s faecal samples prior to allo-HSCT to be re-administered after engraftment is a feasible and effective strategy to reconstitute the microbiota. It remains to be seen whether patients who underwent auto-FMT have better outcomes with regard to these complications and if they have a better overall survival. If the efficacy of this strategy is confirmed, it could also be considered in other situations where significant microbiota disruption is expected, such as broad spectrum or prolonged antibiotic treatment or anticancer chemotherapy.

Conclusion

Although the benefits in terms of haematological outcomes and overall survival still need to be evaluated, auto-FMT is a promising strategy to re-establish the intestinal microbiota after the disorders induced by the antibiotic treatment associated to the allo-HSCT.

Sources

1 Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med 2018 ; 10, eaap9489.

2 Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012 ; 55 : 905-14.

3 Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 2015 ; 21 : 1373-83.

4 Pamer EG, Taur Y, Jenq R, et al. Impact of the intestinal microbiota on infections and survival following hematopoietic stem cell transplantation. Blood 2014 ; 124 : SCI-48.

5 Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroidresistant acute graft-versus-host disease of the gut. Blood 2016 ; 128 : 2083-8.

Tags
Gastroenterology Microbiome Flora
    Focus
    Microbiota 7 - June 2019
    • Overview
      • Digestive cancers and intestinal microbiota: from oncogenesis to response to treatment
    • Commented articles
      • Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant
      • Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition
    • Congress review
      • Review of the main contributions related to the intestinal microbiota
      • Gut Microbiota for Health World Summit 2019
    • Press review
      • The impact of the parents’ microbiome on the descendants health
      • Esophageal microbiome cause or consequence esophageal diseases
    Created 25 August 2021
    Updated 19 August 2024

    About this article

    To know more about this topic.

    Main topic

    Drug

    Content type

    Commented article

    Author

    Image_DT FMT H Sokol Prof Harry Sokol
    Digestive cancers and intestinal microbiota: from oncogenesis to response to treatment
    Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition
    Focus

    Microbiota 7 - June 2019

    Overview

    Digestive cancers and intestinal microbiota: from oncogenesis to response to treatment

    Commented articles

    Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition

    Congress review

    Review of the main contributions related to the intestinal microbiota Gut Microbiota for Health World Summit 2019

    Press review

    The impact of the parents’ microbiome on the descendants health Esophageal microbiome cause or consequence esophageal diseases
    Gastroenterology
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo